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Point/Counterpoint WheatleyUse of transcatheter valve should not be rationedGrayson H. Wheatley III, MDThe emergence of new technologies for the treatment of
aortic valve disorders has brought with it a host of medical
and ethical challenges regarding patient selection and
choice of treatment. Because of the uncertainty around
the safety of new transcatheter aortic valve implantation
(TAVI) technologies, early device trials have focused on en-
rolling and treating patients at high surgical risk who are
‘‘non-operative’’ candidates. Although outcomes for open
surgical repair of critical aortic stenosis are improving,
early results with TAVI are encouraging and have led to ex-
panded patient selection criteria.1-4 Although some
clinicians believe that the use of TAVI should be rationed
in these non-operative patients, there is a strong argument
to make that these patients ethically deserve the same treat-
ment options (when medically appropriate) as younger, less
high-risk patients.
ETHICAL AND TREATMENT DECISIONS
Our hypothetical 75-year-old patient with critical aortic
stenosis, multiple comorbidities, and a prior coronary artery
revascularization with patent bypass grafts has been deter-
mined by the surgical team to be a non-operative candidate,
and this patient’s situation is becoming increasingly com-
mon. Recent data have shown that there are a growing num-
ber of similar patients who are denied surgical therapy
because of comorbidities. Iung and colleagues5 retrospec-
tively showed that 33% of patients referred for aortic valve
replacement were denied surgical repair because of their
high surgical risk. The benefits of aortic valve treatment
with relief of physiologic gradient across the stenotic aortic
valve drastically alters the survival curve of patients com-
pared with medical management.6 However, in patients
with end-stage disease, TAVI has shown promise of extend-
ing life an average of 6 months.7-9 The fundamental
question becomes, should we? Or in other terms, should
we ration health care to patients?
There are 3 different ethical frameworks for which to
consider this case: need principles, maximizing principles,
and egalitarian principles.10 The need principle is based
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ity and supersede all other considerations. This is standard
operating practice for most physician–patient interactions
in today’s healthcare environment. This is the perspective
that all of our patients expect from us when making difficult
and complex decisions. This traditional approach is in-
tended to offer the best possible outcome and intervention
for any patient in need. In this case, it would look simply
at the patient and the feasibility of implanting a percutane-
ous aortic valve. If the patient were deemed a suitable can-
didate, he or shewould be offered this intervention. Because
the patient is a candidate for TAVI, it should be offered to
the patient to improve his or her quality of life and to relieve
suffering. A majority of clinicians would follow this princi-
ple of justice. The facts that the patient did not have a well-
developed support structure to assist him or her after the
procedure and that the patient’s life expectancy is short
are not important drivers of this ethical and moral frame-
work. Essentially, rationing of care is not a consideration
with the need principle, and the patient should be offered
a TAVI procedure.
The second principle of justice in rationing health care is
the maximizing principle. This principle seeks to achieve
the best possible consequences, both for the patient and
for society as a whole. This slightly broader perspective
takes into consideration that this patient has limited support
at home and after TAVI would most likely not return to be-
ing a productive member of society. The total economic
burden of the TAVI procedure, hospitalization, and subse-
quent care facility is a sizable amount and would certainly
have an overall impact on total health care costs. It is diffi-
cult for patients to actively engage in this broader perspec-
tive because it is difficult for them to fully comprehend the
consequences of the therapy in relation to their own debili-
tated state. The intent here is to maximize well-being for the
patient. A TAVI procedure in this patient would certainly
improve his or her well-being, and therefore TAVI would
meet the threshold for rationing in this patient’s case using
the maximizing principle and should be offered to the
patient.
Finally, the egalitarian principle of justice in health care
considers inequalities in health care, and every effort should
be made to reduce these inequalities. The total cost of the
procedure and rehabilitation is sizeable primarily because
of the costs of the percutaneous valve technology compared
with a standard aortic valve replacement. From this per-
spective, the total costs used in the last several months of
this patient’s life might be better served going to a pediatric
patient who has a long prosperous life ahead. As a result, the
egalitarian principle would most likely support rationingery c April 2012
Wheatley Point/Counterpointcare to this patient, and using this moral framework, the
physician should make this informed decision without
much input from the patient. This is also the hardest deci-
sion to make for the physician because the health care sys-
tem as a whole is being considered and the patient is left out
of this decision-making process. The physician standing at
the patient’s bedside must look at society’s costs in light of
the total costs for the patient relative to the expected out-
come. Although this type of decision process may be best
for the health care system in the long run to help decrease
health care expenditures, it is a framework with which we
as clinicians are not yet comfortable. With the passage of
the US health care reform, tough choices are mandatory
to help counteract the increasing health care costs, and ra-
tioning of health care will most likely be a new part of pro-
viding care.11 New technologies, such as TAVI, will
certainly receive a great deal of push-back to ration.
In terms of the possibility of rationing TAVI procedures,
the costs of this procedure need to be compared with other
existing technologies and treatments. Wu and col-
leagues12,13 have looked at the cost-effective ratio (CER)
of standard aortic valve replacement and shown that for
a 75-year-old patient the average CER is $16,500. This is
compared with a CER of $50,000 for TAVI procedures.14
These costs take into consideration the quality of life, hos-
pital costs, and need for extended care. Although this differ-
ence is substantial, a CER between $20,000 and $100,000 is
acceptable to the US health care system.12 As a result, TAVI
procedures are justifiable from a cost analysis.
TAVI has already proven to be a successful and useful
technology for high-risk surgical patients with critical aor-
tic stenosis. The increased procedural and device costs of
TAVI compared with a surgical aortic valve prosthesis and
replacement surgery put TAVI procedures at risk for future
health care rationing as part of health care reform to mini-
mize growing health care costs in the United States. The
CER of TAVI procedures is in line with other existing tech-
nologies and therefore should not be singled out as anThe Journal of Thoracic and Ca‘‘expensive’’ new technology. The principles of justice in
health care rationing also support continued use of TAVI
procedures in high-risk patients. Future new technologies
must face continued evaluation and scrutiny, and physicians
must be prepared to be involved in some degree of health
care rationing in the future.
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